Sumitomo Pharma Co., Ltd.
Sumitomo Pharma is a global pharmaceutical company developing treatments in oncology, CNS and regenerative medicine, combining AI-driven research with drug discovery and manufacturing.
Sumitomo Pharma Co., Ltd. is a pharmaceutical company that discovers, develops and delivers treatments and medicines to patients worldwide. Its work spans the full arc from discovery to delivery, covering drug discovery, translational research and pharmaceutical manufacturing. Therapeutic focus areas include oncology, central nervous system disorders and regenerative medicine.
Technical work at the company draws on artificial intelligence and machine learning, which are integrated into everyday research workflows alongside more traditional laboratory and clinical methods. Researchers, clinicians, business strategists and manufacturing experts work in multidisciplinary teams, with collaboration across disciplines supported by an internal "Value Creation Cycle" intended to shorten the path from discovery to delivery. The company reports a heritage of 100 years supporting global health, and operates on a global scale.
The company states values of rigor, flexibility and compassion, and describes a culture of curiosity that encourages challenging conventional approaches. It emphasises diversity and inclusion, stating that individuals can play an active role irrespective of background or gender. Employee fulfilment and personal wellbeing are prioritised alongside productivity, supported by what the company calls strategic work style innovations.